Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France15 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 72 people, planned
- Started
- May 2026
- Expected to end
- May 2030
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Fecal microbiota transplantation (FMT)
- Sham-transplantation (placebo)
- Record updated
- 17 March 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 44 criteriaShow less
Who can take part
- Males or females
- Age ≥18 and ≤75 years
- Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct changes consistent with PSC
- IBD diagnosed according to international guidelines (presence of endoscopic and histologic signs)
- IBD inactive for at least 6 months (defined by no evidence of flare and no change in treatment)
- ALP ≥ 1.3 ULN (at least 2 times within a 3 months pre-inclusion period) or elevated total bilirubin ≤50 umol/l (with concomitant elevated direct bilirubin)
- Treatment with UDCA (13-23 mg/kg/d) for at least 6 months and at the same dosage for at least 3 months
- Using contraceptive in women of childbearing potential and agrees to pursue it from inclusion until week 48. Women of childbearing potential, i.e. fertile, following menarche and until becoming post-menopaused unless permanently sterile, who are sexually active have to apply a highly effective method of birth control with a low failure rate (i.e. less than 1% per year) when used constantly and correctly
- Written informed consent signed
- Subject affiliated to the French
- Social Security System
Who cannot take part
- History of acute cholangitis in the last 3 months prior to inclusion or current acute cholangitis
- Prior liver transplantation
- Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned within 3 months post randomization date
- History of colorectal carcinoma or high-grade dypsplasia in previous screening colonoscopy
- Current treatment with biologics (anti-TNF agent, vedolizumab, ustekinumab) or JAK inhibitors (tofacitinnib) or prednisone > 10 mg/day or budesonide > 3 mg /day) (or treatment initiated less than one month)
- Participation in another interventional research without prior consultation with the investigator responsible for the patient's monitoring in the present study (participation in other non-interventional studies is permitted)
- No treatment with antibiotics, antifungics or probiotics < 4 weeks
- Hepatic comorbidity: HBV infection (defined by positive Ag HBS), HCV infection (defined by positive HCV RNA), alcohol abuse (defined by alcohol intake > 30g/day), metabolic dysfunction associated steatohepatitis, primary biliary cholangitis, Hemochromatosis, Wilson disease, α1-antitrypsin deficiency, celiac disease
- HIV infection
- History of or established or suspected hepatobiliary carcinoma
- History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to inclusion)
- Dosage changes of treatment for liver disease in the last 3 months or new treatment for liver disease started in the last 3 months
- History of total colectomy
- Current active IBD defined by a partial Mayo score > 2 in patients with ulcerative colitis (UC), unclassed colitis or a Crohn's Disease Activity Index (CDAI) > 150 in patients with Crohn's disease
- Unable to consent, subject to legal or administrative decision (protection measure or deprivation of liberty) or involuntary psychiatric care
- No other hepatic pathology: HBV (positive HBs Ag), HCV (positive HCV antibody and positive PCR), autoimmune hepatitis
- No HIV infection (positive serology HIV1+2 antibodies)
- No documented Clostridium difficile infection at inclusion or < 10 days preceding randomization (in case of infection discovered at inclusion)
- Autoimmune hepatitis defined by the presence of moderate to severe interface hepatitis documented on liver biopsy and at least 1 of the 2 following criteria: AST or ALT > 5 ULN, Positive anti smooth muscle auto antibodies or serum IgG > 1.5 ULN
- AST or ALT > 7 ULN in the last 3 months
- Platelets count in the last 3 months < 100 000/mm3
- Albumin in the last 3 months <35g/L
- Renal insufficiency (clearance<60 ml/min)
- Small duct PSC
- Secondary sclerosing cholangitis (notably IgG4-associated cholangitis)
- Cirrhosis defined by Liver elastometry >14.4 kPa or by current or past decompensation of cirrhosis
- Prothrombin index in the last 3 months < 70%
- Any severe comorbidity that may reduce life expectancy
- Changes in IBD treatment or initiation of a new treatment for IBD in the last 3 months
- Any contra-indication to swallow capsules
- Pregnancy or desire for pregnancy or breastfeeding; Randomization criteria
- No pregnancy (or desire for in the next year)
- Available FMT with EBV and CMV compatibility
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) The aim of the present trial is to assess the efficacy of fecal microbiota transplantation (FMT) on ALP and bilirubin compared to sham transplantation in addition to ursodeoxycholic acid (UDCA) treatment in PSC patients.
The 2 groups in the trial
- Fecal microbiotaTreatment being tested
FMT with stools from healthy donors 3 sessions of FMT in addition to standard UDCA therapy. First session of FMT: during a colonoscopy. Second and third session of FMT: 20 FMT capsules at week 12 and 24
Treatment: Fecal microbiota transplantation (FMT)
- Sham transplantationSham treatment, for comparison
3 sessions of sham transplantation in addition to standard UDCA therapy. First session of sham transplantation: during a colonoscopy Second and third session of sham transplantation: 20 placebo capsules at week 12 and 24.
Treatment: Sham-transplantation (placebo)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from NCT07477782, who can take part
- Record updated
- 17 March 2026